【24h】

Genetic heterogeneity of diffuse large B-cell lymphoma

机译:弥漫性大B细胞淋巴瘤的遗传异质性

获取原文
获取原文并翻译 | 示例
       

摘要

Diffuse large B-cell lymphoma (DLBCL) is the most common form of lymphoma in adults. The disease exhibits a striking heterogeneity in gene expression profiles and clinical outcomes, but its genetic causes remain to be fully defined. Through whole genome and exome sequencing, we characterized the genetic diversity of DLBCL. In all, we sequenced 73 DLBCL primary tumors (34 with matched normal DNA). Separately, we sequenced the exomes of 21 DLBCL cell lines. We identified 322 DLBCL cancer genes that were recurrently mutated in primary DLBCLs. We identified recurrent mutations implicating a number of known and not previously identified genes and pathways in DLBCL including those related to chromatin modification (ARID1A and MEF2B). NF-kB (CARD11 and TNFAIP3), PI3 kinase (PIK3CD, PIK3R1. and MTOR), B-cell lineage (IRF8, POU2F2. and GNA13), and WNT signaling (WIF1). We also experimentally validated a mutation in PIK3CD, a gene not previously implicated in lymphomas. The patterns of mutation demonstrated a classic long tail distribution with substantial variation of mutated genes from patient to patient and also between published studies. Thus, our study reveals the tremendous genetic heterogeneity that underlies lymphomas and highlights the need for personalized medicine approaches to treating these patients.
机译:弥漫性大B细胞淋巴瘤(DLBCL)是成人中最常见的淋巴瘤形式。该病在基因表达谱和临床结果方面表现出惊人的异质性,但其遗传原因仍有待完全确定。通过全基因组和外显子组测序,我们表征了DLBCL的遗传多样性。我们总共对73个DLBCL原发肿瘤进行了测序(34个具有匹配的正常DNA)。另外,我们对21个DLBCL细胞系的外显子组进行了测序。我们确定了322个DLBCL癌症基因,这些基因在原发性DLBCLs中经常发生突变。我们在DLBCL中鉴定了涉及许多已知且未先前鉴定的基因和途径的复发突变,包括与染色质修饰相关的那些(ARID1A和MEF2B)。 NF-kB(CARD11和TNFAIP3),PI3激酶(PIK3CD,PIK3R1和MTOR),B细胞谱系(IRF8,POU2F2和GNA13)和WNT信号传导(WIF1)。我们还通过实验验证了PIK3CD中的突变,该基因先前未与淋巴瘤相关。突变的模式显示出经典的长尾巴分布,每个患者之间以及在已发表的研究之间突变基因的显着变化。因此,我们的研究揭示了淋巴瘤背后巨大的遗传异质性,并强调了需要个性化的医学方法来治疗这些患者。

著录项

  • 来源
  • 作者单位

    Duke Institute for Genome Sciences and Policy, Duke University, Durham, NC 27710,Duke Cancer Institute and Department of Medicine, Duke University, Durham, NC 27710;

    Duke Institute for Genome Sciences and Policy, Duke University, Durham, NC 27710;

    Duke Institute for Genome Sciences and Policy, Duke University, Durham, NC 27710;

    Department of Statistical Science, Duke University, Durham, NC 27710;

    University of North Carolina at Chapel Hill, Chapel Hill, NC 27599;

    University of North Carolina at Chapel Hill, Chapel Hill, NC 27599;

    University of North Carolina at Chapel Hill, Chapel Hill, NC 27599;

    The University of Hong Kong, Queen Mary Hospital, Hong Kong, China;

    The University of Hong Kong, Queen Mary Hospital, Hong Kong, China;

    The University of Hong Kong, Queen Mary Hospital, Hong Kong, China;

    Duke University Medical Center, Durham NC 27710;

    Duke University Medical Center, Durham NC 27710;

    Duke University Medical Center, Durham NC 27710;

    Emory University, Atlanta GA 30322;

    University of North Carolina at Chapel Hill, Chapel Hill, NC 27599;

    Emory University, Atlanta GA 30322;

    Imperial College, London, United Kingdom;

    University of Massachusetts, Worcester, MA 01655;

    Northwestern University, Chicago IL 60208;

    Indiana University, Indianapolis IN 46202;

    Baylor University Medical Center, Dallas TX 75246;

    Cleveland Clinic, Cleveland, OH 44195;

    Duke Institute for Genome Sciences and Policy, Duke University, Durham, NC 27710;

    Duke Institute for Genome Sciences and Policy, Duke University, Durham, NC 27710;

    Duke Institute for Genome Sciences and Policy, Duke University, Durham, NC 27710;

    Duke Institute for Genome Sciences and Policy, Duke University, Durham, NC 27710;

    Division of Hematology and Comprehensive Cancer Center, Ohio State University, Columbus, OH 43210;

    Division of Hematology and Comprehensive Cancer Center, Ohio State University, Columbus, OH 43210;

    Division of Hematology and Comprehensive Cancer Center, Ohio State University, Columbus, OH 43210;

    Duke University Medical Center, Durham NC 27710;

    Genetics and Development Biology Center, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD 20892;

    Genetics and Development Biology Center, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD 20892;

    Northwestern University, Chicago IL 60208;

    Hudson Alpha Institute for Biotechnology, Huntsville, AL 35806;

    Department of Statistical Science, Duke University, Durham, NC 27710;

    Duke Institute for Genome Sciences and Policy, Duke University, Durham, NC 27710,Duke Cancer Institute and Department of Medicine, Duke University, Durham, NC 27710,Duke University Medical Center, Durham NC 27710;

  • 收录信息 美国《科学引文索引》(SCI);美国《生物学医学文摘》(MEDLINE);美国《化学文摘》(CA);
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

    next-generation sequencing; cancer genetics; cancer heterogeneity;

    机译:下一代测序癌症遗传学;癌症异质性;
  • 入库时间 2022-08-18 00:39:50

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号